Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) were down 8.1% during trading on Tuesday . The stock traded as low as $2.55 and last traded at $2.60. Approximately 619,221 shares changed hands during trading, an increase of 1% from the average daily volume of 614,082 shares. The stock had previously closed at $2.83.

Several analysts recently commented on BDSI shares. Roth Capital set a $5.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Monday, November 13th. Cantor Fitzgerald set a $5.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Thursday, October 12th. HC Wainwright set a $5.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Friday, October 13th. Finally, Piper Jaffray Companies set a $4.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Sunday, October 22nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $4.29.

The firm has a market capitalization of $145.30, a P/E ratio of 28.89 and a beta of 0.74. The company has a quick ratio of 1.07, a current ratio of 1.28 and a debt-to-equity ratio of 1.89.

BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01. The company had revenue of $11.25 million for the quarter, compared to analyst estimates of $9.40 million. BioDelivery Sciences International had a return on equity of 33.83% and a net margin of 10.40%. The firm’s revenue for the quarter was up 215.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.30) earnings per share. equities analysts expect that BioDelivery Sciences International, Inc. will post 0.16 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Advisor Group Inc. boosted its stake in BioDelivery Sciences International by 42.1% during the second quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock worth $126,000 after buying an additional 13,341 shares during the last quarter. Royce & Associates LP acquired a new position in BioDelivery Sciences International during the third quarter worth $3,814,000. Stonepine Capital Management LLC boosted its stake in BioDelivery Sciences International by 22.2% during the second quarter. Stonepine Capital Management LLC now owns 3,477,673 shares of the specialty pharmaceutical company’s stock worth $9,737,000 after buying an additional 632,853 shares during the last quarter. GSA Capital Partners LLP boosted its stake in BioDelivery Sciences International by 10.1% during the second quarter. GSA Capital Partners LLP now owns 488,767 shares of the specialty pharmaceutical company’s stock worth $1,369,000 after buying an additional 44,700 shares during the last quarter. Finally, EAM Investors LLC boosted its stake in BioDelivery Sciences International by 62.1% during the third quarter. EAM Investors LLC now owns 780,635 shares of the specialty pharmaceutical company’s stock worth $2,303,000 after buying an additional 299,163 shares during the last quarter. 44.08% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/01/17/biodelivery-sciences-international-bdsi-stock-price-down-8-1.html.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.